C4 Therapeutics Inc (NAS:CCCC)
$ 4.31 0.12 (2.86%) Market Cap: 295.77 Mil Enterprise Value: 123.46 Mil PE Ratio: 0 PB Ratio: 1.26 GF Score: 60/100

C4 Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 11, 2024 / 05:00PM GMT
Release Date Price: $7.24 (-5.97%)
Eric Joseph JPMorgan;Moderator

All right. Good morning. I'm Eric Joseph, senior biotech analyst at JPMorgan. And our next presenting company this morning is C4 Therapeutics. Presenting on behalf of the company is CEO, Andrew Hirsch, there's a Q&A session after the presentation, just raise your hand, we'll bring a mic over to you before asking your question and for folks tuning in via the webcast feel free to submit questions via the portal.

So with that, Andrew, thanks for joining us.

Andrew Hirsch C4 Therapeutics Inc;CEO

Great. Thank you, Eric, and thanks to JPMorgan for having us here today. So before I begin, I wanted to just comment that I'll be making forward-looking statements today. Obviously, those are subject to various risks and uncertainties, and you should look at the risk factors section of our SEC filings to understand what those risks and uncertainties are.

So for those of you new to C4, C4 was a recognized leader in the world of targeted protein degradation. In fact, one of the pioneers. We were started in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot